Researchers at the Karlsruhe Institute of Technology have identified a molecular target that could help alter the protective environment surrounding pancreatic tumors, potentially making the cancer more vulnerable to immune attack. The work centers on CD44, a molecule that helps regulate cancer-associated fibroblasts in the tumor microenvironment.
The findings, published in Cell Death & Disease, are based on experiments in a mouse model and human cells. They do not establish a treatment for patients, but they identify a mechanism that researchers say could inform future combination approaches for one of the hardest cancers to treat.
Why the surrounding tissue matters
Pancreatic cancer is difficult to treat in part because the tumor is surrounded by dense tissue that can act as both a physical and biological barrier. This tumor microenvironment includes supporting cells, blood vessels and immune cells, and can account for as much as 90% of a pancreatic tumor’s mass.
A key component is the cancer-associated fibroblast, or CAF. These altered connective-tissue cells help create a scar-like extracellular structure around the tumor. They can also support tumor growth and spread while suppressing immune activity.
That immune-suppressing environment helps explain why immunotherapies that work in some other cancers have often been less effective in pancreatic cancer. Rather than focusing only on tumor cells, the KIT team examined a part of the local tissue system that helps sustain them.
CD44’s role in fibroblast activation
The researchers found that CD44 intensifies signals that activate cancer-associated fibroblasts. In their experiments, inactivating CD44 changed the cells’ behavior: the fibroblasts produced less extracellular matrix, released fewer cytokines and lost features associated with immune suppression.
Those shifts are significant because they suggest the tumor environment may be changeable rather than fixed. If fibroblasts can be moved away from a tumor-supporting state, immune cells may have a better opportunity to reach and attack cancer cells.
In the reported mouse-model experiments, immune cells attacked tumor cells more successfully after CD44 was inactivated, and tumor size decreased. The researchers also studied human cells in the laboratory, supporting the idea that the mechanism is not limited to a single experimental system.
An early-stage route toward combination treatment
The study should be read as preclinical research, not evidence that a CD44-directed therapy is ready for clinical use. Results in cell systems and mouse models do not necessarily translate into safe or effective treatments for people.
Still, the work points to a possible strategy for addressing pancreatic cancer’s unusually resistant microenvironment. Instead of trying only to destroy tumor cells directly, a future treatment approach could seek to reduce the defenses built by surrounding fibroblasts and then combine that intervention with immune-based or other anticancer therapies.
That distinction matters. The dense tissue around pancreatic tumors has often been viewed as an obstacle to drug delivery and immune activity. The KIT findings frame it as a biologically active system whose behavior may be influenced through specific molecular pathways.
What comes next
Further work will be needed to determine whether suppressing CD44 can be done safely, which patients might benefit, and how such an approach could interact with existing treatments. Researchers will also need to test whether the observed effects persist across different pancreatic cancer settings.
For now, the study adds evidence that the tumor microenvironment is a meaningful therapeutic target. By identifying CD44 as a regulator of tumor-supporting fibroblasts, the researchers have provided a concrete lead for efforts to make pancreatic cancer less protected from the body’s immune response.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
